NBIX logo

Neurocrine Biosciences (NBIX) Operating Expenses

Annual Operating Expenses

$1.45 B
+$236.10 M+19.41%

December 31, 2023

Summary

Performance

1-Year Change

+19.41%

3-Year Change

+105.08%

5-Year Change

+258.93%

15-Year Change

+454.99%

NBIX Operating Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

93.01%
NBIX annual total operating expenses is higher than 93.01% of companies in Healthcare sector

High & Low

All-time High

$1.45 B
NBIX annual total operating expenses is currently at an all-time high

3-Year Low

$911.40 M
NBIX annual total operating expenses is currently +59.38% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
NBIX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

N/A
NBIX next annual earnings announcement has not yet been scheduled

OtherNBIXexpensesmetrics:

Annual Total Expenses

$1.49 B
NBIX annual total expenses is $1.49 billion

Annual Interest Expense

$4.60 M
NBIX annual interest expense is $4.60 million

Annual Income Tax

$82.40 M
NBIX annual income tax is $82.40 million

Annual Cost Of Goods Sold

$39.70 M
NBIX annual cost of goods sold is $39.70 million

Quarterly Operating Expenses

$429.30 M
-$3.80 M-0.88%

September 30, 2024

Summary

Performance

3-Month Change

-0.88%

1-Year Change

+23.93%

3-Year Change

+42.67%

5-Year Change

+230.74%

NBIX Quarterly Operating Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

92.71%
NBIX quarterly total operating expenses is higher than 92.71% of companies in Healthcare sector

High & Low

All-time High

$433.10 M
NBIX quarterly total operating expenses is currently -0.88% below its historical high of $433.10 million

3-Year Low

$243.90 M
NBIX quarterly total operating expenses is currently +76.01% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
NBIX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

N/A
NBIX next earnings announcement has not yet been scheduled

OtherNBIXexpensesmetrics:

Quarterly Total Expenses

$437.30 M
NBIX quarterly total expenses is $437.30 million

Quarterly Interest Expense

-
NBIX quarterly interest expense value is unknown

Quarterly Income Tax

$60.50 M
NBIX quarterly income tax is $60.50 million

Quarterly Cost Of Goods Sold

$8.00 M
NBIX quarterly cost of goods sold is $8.00 million

Operating Expenses Formula

Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses

Annual Operating Expenses

$1.45 B
NBIX annual total operating expenses is $1.45 billion

Annual SGA

$887.60 M
NBIX annual SGA is $887.60 million

Annual D&A

$21.30 M
NBIX annual depreciation & amortization is $21.30 million

NBIX Operating Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+19.4%+23.9%
3 y3 years+105.1%+42.7%
5 y5 years+258.9%+230.7%

NBIX Operating Expenses Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+59.4%-0.9%+76.0%
5 y5-yearat high+162.2%-0.9%+174.1%
alltimeall timeat high+8296.5%-0.9%>+9999.0%

Neurocrine Biosciences Operating Expenses History

DateAnnualQuarterly
Sep 2024
-
$429.30 M(-0.9%)
Jun 2024
-
$433.10 M(+7.6%)
Mar 2024
-
$402.50 M(+12.9%)
Dec 2023
$1.45 B(+19.4%)
$356.40 M(+2.9%)
Sep 2023
-
$346.40 M(-5.8%)
Jun 2023
-
$367.60 M(-3.8%)
Mar 2023
-
$382.20 M(+27.0%)
Dec 2022
$1.22 B(+33.5%)
$300.90 M(+2.3%)
Sep 2022
-
$294.00 M(-7.8%)
Jun 2022
-
$318.70 M(+5.2%)
Mar 2022
-
$302.90 M(+24.2%)
Dec 2021
$911.40 M(+28.7%)
$243.90 M(-1.4%)
Sep 2021
-
$247.30 M(+13.4%)
Jun 2021
-
$218.00 M(+7.8%)
Mar 2021
-
$202.20 M(+16.7%)
Dec 2020
$708.30 M(+27.8%)
$173.20 M(-4.6%)
Sep 2020
-
$181.60 M(+2.4%)
Jun 2020
-
$177.40 M(+0.7%)
Mar 2020
-
$176.10 M(+12.5%)
Dec 2019
$554.10 M(+36.9%)
$156.60 M(+20.6%)
Sep 2019
-
$129.80 M(-8.9%)
Jun 2019
-
$142.50 M(+13.8%)
Mar 2019
-
$125.20 M(+21.2%)
Dec 2018
$404.70 M(+54.6%)
$103.33 M(+7.8%)
Sep 2018
-
$95.88 M(-2.1%)
Jun 2018
-
$97.90 M(-9.0%)
Mar 2018
-
$107.58 M(+107.2%)
Dec 2017
$261.73 M(+61.2%)
$51.92 M(-21.7%)
Sep 2017
-
$66.34 M(+4.4%)
Jun 2017
-
$63.54 M(-20.5%)
Mar 2017
-
$79.93 M(+72.8%)
Dec 2016
$162.37 M(+42.5%)
$46.25 M(+20.3%)
Sep 2016
-
$38.44 M(-8.1%)
Jun 2016
-
$41.83 M(+16.7%)
Mar 2016
-
$35.86 M(+16.6%)
Dec 2015
$113.97 M(+76.9%)
$30.75 M(-14.2%)
Sep 2015
-
$35.84 M(+41.6%)
Jun 2015
-
$25.32 M(+14.8%)
Mar 2015
-
$22.06 M(+7.8%)
Dec 2014
$64.41 M(+22.5%)
$20.47 M(+21.4%)
Sep 2014
-
$16.86 M(+17.4%)
Jun 2014
-
$14.36 M(+12.9%)
Mar 2014
-
$12.72 M(+3.8%)
Dec 2013
$52.60 M(+1.8%)
$12.26 M(-3.7%)
Sep 2013
-
$12.73 M(-8.4%)
Jun 2013
-
$13.90 M(+1.4%)
Mar 2013
-
$13.71 M(+2.5%)
Dec 2012
$51.69 M(+18.9%)
$13.37 M(+0.3%)
Sep 2012
-
$13.32 M(+11.5%)
Jun 2012
-
$11.95 M(-8.5%)
Mar 2012
-
$13.06 M(+22.5%)
Dec 2011
$43.49 M(-7.9%)
$10.66 M(-4.7%)
Sep 2011
-
$11.19 M(+1.2%)
Jun 2011
-
$11.06 M(+4.6%)
Mar 2011
-
$10.57 M(-23.3%)
Dec 2010
$47.22 M
$13.79 M(+15.1%)
Sep 2010
-
$11.98 M(+13.8%)
DateAnnualQuarterly
Jun 2010
-
$10.53 M(-3.6%)
Mar 2010
-
$10.92 M(-16.1%)
Dec 2009
$54.07 M(-39.4%)
$13.02 M(+25.6%)
Sep 2009
-
$10.37 M(-33.7%)
Jun 2009
-
$15.63 M(+3.9%)
Mar 2009
-
$15.04 M(-48.8%)
Dec 2008
$89.22 M(-58.2%)
$29.39 M(+78.5%)
Sep 2008
-
$16.46 M(-21.0%)
Jun 2008
-
$20.85 M(-7.4%)
Mar 2008
-
$22.51 M(-82.6%)
Dec 2007
$213.47 M(+39.9%)
$129.13 M(+339.7%)
Sep 2007
-
$29.37 M(+6.4%)
Jun 2007
-
$27.60 M(+0.8%)
Mar 2007
-
$27.38 M(+6.5%)
Dec 2006
$152.55 M(+2.4%)
$25.70 M(-37.7%)
Sep 2006
-
$41.27 M(+7.2%)
Jun 2006
-
$38.51 M(-18.2%)
Mar 2006
-
$47.07 M(+21.6%)
Dec 2005
$148.96 M(+8.3%)
$38.70 M(-2.3%)
Sep 2005
-
$39.62 M(+0.5%)
Jun 2005
-
$39.42 M(+26.3%)
Mar 2005
-
$31.21 M(-21.3%)
Dec 2004
$137.51 M(-30.5%)
$39.67 M(+5.1%)
Sep 2004
-
$37.73 M(+32.7%)
Jun 2004
-
$28.44 M(-10.2%)
Mar 2004
-
$31.67 M(-28.8%)
Dec 2003
$197.87 M(+62.6%)
$44.51 M(+3.9%)
Sep 2003
-
$42.83 M(-25.5%)
Jun 2003
-
$57.46 M(+8.3%)
Mar 2003
-
$53.07 M(+17.5%)
Dec 2002
$121.66 M(+42.9%)
$45.15 M(+64.3%)
Sep 2002
-
$27.48 M(+4.7%)
Jun 2002
-
$26.25 M(+15.2%)
Mar 2002
-
$22.78 M(-19.3%)
Dec 2001
$85.12 M(+62.5%)
$28.24 M(+38.4%)
Sep 2001
-
$20.40 M(+7.8%)
Jun 2001
-
$18.92 M(+7.7%)
Mar 2001
-
$17.57 M(+13.8%)
Dec 2000
$52.39 M(+35.0%)
$15.44 M(-0.9%)
Sep 2000
-
$15.57 M(+43.4%)
Jun 2000
-
$10.86 M(+3.2%)
Mar 2000
-
$10.52 M(+7.4%)
Dec 1999
$38.80 M(+28.9%)
$9.80 M(-8.4%)
Sep 1999
-
$10.70 M(+12.6%)
Jun 1999
-
$9.50 M(+9.2%)
Mar 1999
-
$8.70 M(+1.2%)
Dec 1998
$30.10 M(+11.9%)
$8.60 M(-1.1%)
Sep 1998
-
$8.70 M(+42.6%)
Jun 1998
-
$6.10 M(-11.6%)
Mar 1998
-
$6.90 M(-12.7%)
Dec 1997
$26.90 M(+55.5%)
$7.90 M(+14.5%)
Sep 1997
-
$6.90 M(+15.0%)
Jun 1997
-
$6.00 M(+1.7%)
Mar 1997
-
$5.90 M(-6.3%)
Dec 1996
$17.30 M
$6.30 M(+57.5%)
Sep 1996
-
$4.00 M(-9.1%)
Jun 1996
-
$4.40 M(+69.2%)
Mar 1996
-
$2.60 M

FAQ

  • What is Neurocrine Biosciences annual total operating expenses?
  • What is the all time high annual operating expenses for Neurocrine Biosciences?
  • What is Neurocrine Biosciences annual operating expenses year-on-year change?
  • What is Neurocrine Biosciences quarterly total operating expenses?
  • What is the all time high quarterly operating expenses for Neurocrine Biosciences?
  • What is Neurocrine Biosciences quarterly operating expenses year-on-year change?

What is Neurocrine Biosciences annual total operating expenses?

The current annual operating expenses of NBIX is $1.45 B

What is the all time high annual operating expenses for Neurocrine Biosciences?

Neurocrine Biosciences all-time high annual total operating expenses is $1.45 B

What is Neurocrine Biosciences annual operating expenses year-on-year change?

Over the past year, NBIX annual total operating expenses has changed by +$236.10 M (+19.41%)

What is Neurocrine Biosciences quarterly total operating expenses?

The current quarterly operating expenses of NBIX is $429.30 M

What is the all time high quarterly operating expenses for Neurocrine Biosciences?

Neurocrine Biosciences all-time high quarterly total operating expenses is $433.10 M

What is Neurocrine Biosciences quarterly operating expenses year-on-year change?

Over the past year, NBIX quarterly total operating expenses has changed by +$82.90 M (+23.93%)